Loading...

IRD OPUS GENETICS INC Company Mergers 8-K Filing

PS G

RD

OPUS GENETICS INC

(IRD)

2025 8-K

Summary

Summary

Clinical Trial Update

New CFO Appointment

Private Placement Done

Financial Results Announced

Product Expansion

Market Expansion

Product Expansion

Financial Statements

Agreement Termination

Financial Results

Financial Results

Bylaw Amendments

Patent Challenge

Executive Changes

Annual Meeting Notice

Equity Offering

Acquisition Completed

Financial Results

Merger Completion

Q2 Financial Results

Amendment and Restated Bylaws

Regulation FD Disclosure

Earnings Reports

Consulting Agreement with D...

Investor Meetings

Financial Results Announcement

Appointment of CFO

Appointment of Chief Busine...

Appointment of Chief Operat...

Financial Results Announcement

Corporate Presentation and ...

Appointment of CEO

FDA Approval and Milestone ...

Stock Purchase Agreement

Regulation FD Disclosure

Departure of CEO

Annual Meeting Results

Bylaws Amendment

Financial Results Announcement

Termination of CEO and Appo...

Financial Results Announcement

Earnings Reports

External Links:

Opus Genetics, Inc. announced on July 22, 2025, a funding and license agreement allowing for up to $1.6 million to develop gene therapies for inherited retinal degeneration associated with the RDH12 gene.

AI Assistant

OPUS GENETICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.